NAD advises removing Removyl claims
This article was originally published in The Tan Sheet
Green tea studies fail to substantiate weight-loss claims for Removyl Advanced Formula dietary supplements, the National Advertising Division says in its recommendation to discontinue the claims. NAD July 7 said Removyl Corp. Ltd. argued the product's efficacy is based on botanical ingredients that are purgative and diuretic in nature and on green tea extract, camellia sinensis. The Council of Better Business Bureaus division said evidence does not support specific fast weight-loss claims for Removyl like "You are going to notice that your weight will have dropped by almost one pound in as little as 8 hours." In the inquiry made in its ongoing monitoring program and as part of its initiative with the Council for Responsible Nutrition, NAD recommended limiting future advertising to claims for the benefits of green tea, and the diuretic and purgative properties of botanicals in Removyl. The Henderson, Nev.-based firm said it has not offered the product for sale since April, but it is shipping remaining orders
You may also be interested in...
With list due 4 November, there may not be time for public comment. Meanwhile, where will biopharma find fill/finish capacity?
Lorbrena is approved as a second-line treatment for ALK-positive NSCLC but Pfizer believes data from the first-line Phase III CROWN study makes the drug a serious competitor to standard of care Alecensa in the first-line setting.
A new analysis of the ADAURA study shows that Tagrisso’s disease-free survival benefits in early stage EGFRm NSCLC are replicated for brain metastases, a common complication with a poor prognosis. Filings and OS data await.